Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis

M. Adnan Nadir, Li Wei, Douglas H. J. Elder, Renata Libianto, Tiong K. Lim, Maheshwar Pauriah, Stuart D. Pringle, Alex D. Doney, Anna-Maria Choy, Allan D. Struthers, Chim C. Lang (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    100 Citations (Scopus)

    Abstract

    Objectives The purpose of this study was to investigate the impact of renin-angiotensin system blockade therapy on outcomes in aortic stenosis (AS).

    Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are perceived to be relatively contraindicated in AS. However, inhibitors of the renin-angiotensin system may be beneficial in AS through their cardioprotective and beneficial effects on left ventricular remodeling.

    Methods The Health Informatics dispensed prescribing, morbidity, and mortality database for the population of Tayside, Scotland, was linked through a unique patient identifier to the Tayside echocardiography database (> 110,000 scans). Patients with a diagnosis of AS from 1993 to 2008 were identified. Cox regression model (adjusted for confounding variables) and propensity score analysis were used to assess the impact of ACEIs or ARBs on all-cause mortality and cardiovascular (CV) events (CV death or hospitalizations).

    Results A total of 2,117 patients with AS (mean age 73 +/- 12 years, 46% men) were identified and 699 (33%) were on ACEI or ARB therapy. Over a mean follow-up of 4.2 years, there were 1,087 (51%) all-cause deaths and 1,018 (48%) CV events. Those treated with ACEIs or ARBs had a significantly lower all-cause mortality with an adjusted hazard ratio of 0.76 (95% confidence interval: 0.62 to 0.92, p < 0.0001) and fewer CV events with an adjusted hazard ratio of 0.77 (95% confidence interval: 0.65 to 0.92, p < 0.0001). The outcome benefits of ACEIs/ARBs were further supported by propensity score analysis.

    Conclusions This large observational study suggests that ACEI/ARB therapy is associated with an improved survival and a lower risk of CV events in patients with AS. (J Am Coll Cardiol 2011;58:570-6) (C) 2011 by the American College of Cardiology Foundation

    Original languageEnglish
    Pages (from-to)570-576
    Number of pages7
    JournalJournal of the American College of Cardiology
    Volume58
    Issue number6
    DOIs
    Publication statusPublished - 2 Aug 2011

    Keywords

    • Angiotensin-converting enzyme inhibitors
    • Angiotensin receptor blockers
    • Aortic stenosis
    • Converting enzyme inhibitors
    • Pressure overload hypertrophy
    • Left ventricular hypertrophy
    • Normal coronary arteries
    • Valve disease
    • Heart failure
    • Diastolic disfunction
    • Delay progression
    • Replacement
    • Angina

    Cite this